PubMed Health⌕ Search

Biomedical subjects

Małgorzata Sidorkiewicz

Publications and source records attributed to Małgorzata Sidorkiewicz.

4 recordsLinked to original sources
PubMed2006

[Late spontaneous elimination of HCV-RNA from mononuclear cells derived from peripheral blood in patients with chronic hepatitis C].

THE AIM: To follow persistence of HCV-RNA in PBMC in patients with chronic hepatitis C (CHC). To estimate the influence of this phenomenon on the cellular immune response of peripheral blood lymphocytes. MATERIAL AND METHODS: 8 HCV-RNA in PBMC positive children, with undetectable serum HCV-RNA after antiviral treatment, have been examined every 2-3 years. The amount of IFN-gamma, IL-12 and IL-18 secreted by PBMC obtained from the children after stimulation with phytohemagglutinin (PHA) was measured. RESULTS: Spontaneous elimination of HCV-RNA from PBMC in 2 to 6 years after treatment was found in all children. In two children HCV-RNA detectable both in serum and in PBMC, without recurrence of hepatitis, was found in single examination. PBMC containing HCV-RNA secreted more IFN-gamma than PBMC lacking it (1221 +/- 458 pg/ml vs. 651 +/- 147 pg/ml; p=0.009, similar correlation was revealed with the regard of IL-12: 21.8 +/- 12.3 pg/ml vs. 5,6 +/- 3,3 pg/ml respectively; p=0.009. Production and release of IL-18 were not correlated with HCV-RNA persistence (p=0.12). CONCLUSION: Patients with CHC and persistence of HCV-RNA in PBMC require longitudinal follow-up in the respect of possible reseroconversion. PBMC containing HCV-RNA reveal enhanced cellular immune response, which most probably effects in spontaneous elimination of the virus.

Adolescent↗
PubMed2003

A competitor DNA template for the molecular quantification of the hepatitis B virus.

The molecular determination of viral load in the serum represents the most valuable prognostic marker of HBV infection. In this paper, a new molecular assay for the quantitative measurement of HBV presence is described. It is based on PCR performing with a HBV-specific competitor DNA template. For the construction of the DNA template, a HBV DNA-originated 436 bp DNA fragment was modified by introducing a 110 bp deletion and cloned into pUC19. The resulting vector serves as the competitor DNA template in the competitive PCR. Post-PCR, the competitor DNA generates an amplified fragment of 306 bp; it could be easily distinguished from the product generated from the viral-originated DNA product (416 bp) when the same primers are used. The quantitative ratio between the two products enables the quantitative determination of viral load. The range of the HB-PCR assay is from 3 x 10(4)to 6 x 10(10) particles/ml. A serum HBV load determination performed by HB-PCR assay indicated a close correlation with the results of the Quantiplex HBV DNA assay (bDNA). The HB-PCR assay is cheap, reliable and easy to use in any laboratory working with PCR methods.

DNA, Viral↗
PubMed2002

[HLA class II alleles and response to hepatitis C treatment with interferon alpha2b].

BACKGROUND/AIMS: The mechanisms of humoral immunological response in chronic hepatitis C are not fully understood. It would be interesting to correlate HLA II alleles with the therapeutic response to interferon alfa2b treatment in patients with chronic hepatitis C. Such correlation has not yet been described. The purpose of the study was to correlate the presence of HLA alleles in chronic hepatitis C patients with results of interferon-alfa2b therapy. METHODS: We assessed HCV-RNA presence in serum by RT-PCR and HLA-DR B*1/alleles by PCR-SSP for locus I and II in 54 patients with chronic hepatitis C. All patients were treated with interferon alfa2b for six month. Results of the therapy were evaluated 18 months after the end of treatment. RESULTS: Based on the treatment results (TR--therapeutic response) patients were retrospectively qualified into three groups: sustained responders (SR)--18.6% (10/54), relapsers (R)--48.1% (26/54), non responders (NR)--33.3% (18/54). Allele DRB*1 07 and allele DRB1* 13 were more frequent among patients in NR and TR group, respectively. Observed differences were not statistically significant (p > 0.05). CONCLUSION: In the group of 54 adults with chronic hepatitis C no correlation between the presence of HLA-DRB1* alleles and response to interferon alfa2b therapy was found.

Adult↗